Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients

References

• Fouchier RA, Rimmelzwaan GF, Kuiken T, et al. Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human coronaviruses. Curr Opin Infect Dis. 2005;18(2):141–146.
   PubMedGoogle Scholar
• Ison MG. Respiratory viral infections in transplant recipients. Curr Opin Organ Transplant. 2005;10(4):312–319.
   Web of Science ®Google Scholar
• Manuel O, Estabrook M. AST ID community of practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):212–219.
   PubMed Web of Science ®Google Scholar
• Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–526.
   PubMed Web of Science ®Google Scholar
• Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11(5):1071–1078.
   PubMed Web of Science ®Google Scholar
• Peghin M, Hirsch HH, Len O, et al. Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study. Am J Transplant. 2016; published online. 12 September 2016. 10.1111/ajt.14042
   PubMedGoogle Scholar
• Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis. 2011;52(Suppl 4):S326–30.
   PubMed Web of Science ®Google Scholar
• Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev. 2008;21(4):716–747.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen BG, De Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–724.
   PubMed Web of Science ®Google Scholar
• Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis. 2001;3(3):138–148.
   PubMedGoogle Scholar
• Lopez-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007;84(7):851–856.
   PubMed Web of Science ®Google Scholar
• Chu HY, Renaud C, Ficken E, et al. Respiratory tract infections due to human metapneumovirus in immunocompromised children. J Pediatric Infect Dis Soc. 2014;3(4):286–293.
   PubMedGoogle Scholar
• Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant. 2007;26(9):883–889.
   PubMed Web of Science ®Google Scholar
• Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005;5(10):2555–2559.
   PubMed Web of Science ®Google Scholar
• Shahda S, Carlos WG, Kiel PJ, et al. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13(3):324–328.
   PubMed Web of Science ®Google Scholar
• Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193(6):760–764.
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rhinehart E, Jackson M, et al. Health care infection control practices advisory committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 Suppl 2):S65–164.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.
   PubMed Web of Science ®Google Scholar
• Johnstone J, Majumdar SR, Fox JD, et al. Human metapneumovirus pneumonia in adults: results of a prospective study. Clin Infect Dis. 2008;46(4):571–574.
   PubMed Web of Science ®Google Scholar
• Preiksaitis CM, Kuypers JM, Fisher CE, et al. A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. J Clin Virol. 2015;62:98–102.
   PubMed Web of Science ®Google Scholar
• Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation. 2010 Apr 27;89(8):1028–1033.
   PubMed Web of Science ®Google Scholar
• Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006 Jul;28(1):131–137.
   PubMed Web of Science ®Google Scholar
• Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5(8):2031–2036.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Lyu DM, Li S, et al. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis. 2010;12(4):330–335.
   PubMed Web of Science ®Google Scholar
• McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22(7):745–753.
   PubMed Web of Science ®Google Scholar
• Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther. 2011;16(5):733–740.
   PubMed Web of Science ®Google Scholar
• Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the midwestern respiratory virus collaborative. Transpl Infect Dis. 2016;18(2):210–215.
   PubMed Web of Science ®Google Scholar
• Forman MS, Advani S, Newman C, et al. Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. J Clin Virol. 2012;55(2):168–172.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Hoffman JA, Practice A. Adenovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):206–211.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14(6):555–563.
   PubMed Web of Science ®Google Scholar
• Humar A, Doucette K, Kumar D, et al. Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. J Heart Lung Transplant. 2006;25(12):1441–1446.
   PubMed Web of Science ®Google Scholar
• Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998 Oct;116(4):617–623.
   PubMed Web of Science ®Google Scholar
• Ganapathi L, Arnold A, Jones S, et al. Use of cidofovir in pediatric patients with adenovirus infection. F1000Res. 2016;5:758.
   PubMedGoogle Scholar
• Mayeur N, Srairi M, Tetu L, et al. Lethal hemorrhagic alveolitis after adenovirus pneumonia in a lung transplant recipient. Heart Lung. 2012 Jul-Aug;41(4):401–403.
   PubMed Web of Science ®Google Scholar
• Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008 Oct;21(4):704–715.
   PubMed Web of Science ®Google Scholar
• Schultze-Florey RE, Tischer S, Schwerk N, et al. Monitoring of adenovirus (ADV)-specific T cells in a boy with ADV pneumonia and disseminated disease after lung transplantation. Transpl Infect Dis. 2016;18(5):756–760.
   PubMed Web of Science ®Google Scholar
• Mmy W, Cw S. Anti-viral drugs for human adenoviruses. Pharmaceuticals. 2010;3(10):3343–3354.
   Google Scholar
• Wold WS, Toth K. New drug on the horizon for treating adenovirus. Expert Opin Pharmacother. 2015;16(14):2095–2099.
   PubMed Web of Science ®Google Scholar
• Seidemann K, Heim A, Pfister ED, et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant. 2004;4(12):2102–2108.
   PubMed Web of Science ®Google Scholar
• Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999 Feb;36(2):127–143.
   PubMed Web of Science ®Google Scholar
• Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005;10(2):225–229.
   PubMed Web of Science ®Google Scholar
• Refaat M, McNamara D, Teuteberg J, et al. Successful cidofovir treatment in an adult heart transplant recipient with severe adenovirus pneumonia. J Heart Lung Transplant. 2008;27(6):699–700.
   PubMed Web of Science ®Google Scholar
• Saquib R, Melton LB, Chandrakantan A, et al. Disseminated adenovirus infection in renal transplant recipients: the role of cidofovir and intravenous immunoglobulin. Transpl Infect Dis. 2010;12(1):77–83.
   PubMed Web of Science ®Google Scholar
• Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant. 2001;27(6):621–626.
   PubMed Web of Science ®Google Scholar
• Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis. 2004;38(1):45–52.
   PubMed Web of Science ®Google Scholar
• Vistide prescribing information: Gilead Sciences. Foster City, CA; 2010.
   Google Scholar
• Florescu DF, Keck MA. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Exp Rev Anti Infect Ther. 2014;12(10):1171–1178.
   PubMed Web of Science ®Google Scholar
• Phase III, open-labeled, multicenter study of the safety and efficacy of brincidofovir (CXM001) in the treatment of early verus late adenovirus infection (CXM001 Adv). Available at: https://clinicaltrials.gov/ct2/show/record/NCT02087306. Accessed January 12, 2017.
   Google Scholar
• Grimley M, Papanicolaou G, Prasad VK, et al. Treatment of adenovirus (AdV) infection in allogeneic hematopoietic cell transplant (HCT) patients (pts) with brincidofovir: 24-week interim results from the AdVise trial. ID Week 2016. New Orleans, LA: Infectious Diseases Society of America; abstract. p. 2339.
   Google Scholar
• Chimerix announces presentation at IDWeek of detailed 24-week results from AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic hematopoietic cell transplant recipients. Available at: http://ir.chimerix.com/releasedetail.cfm?releaseid=995971. Accessed January 6, 2017.
   Google Scholar
• Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012 May;18(5):731–738.
   PubMed Web of Science ®Google Scholar
• Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother. 2015 Oct;49(10):1125–1135.
   PubMed Web of Science ®Google Scholar
• Toth K, Ying B, Tollefson AE, et al. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses. 2015 Mar 23;7(3):1409–1428.
   PubMed Web of Science ®Google Scholar
• Noell BC, Dawson KL, Seethamraju H. Effect of hypogammaglobulinemia on the incidence of community-acquired respiratory viral infections after lung transplantation. Transplant Proc. 2013 Jul-Aug;45(6):2371–2374.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Lankester AC, Van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis. 2005;191(4):520–530.
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83.
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, et al. Centers for disease control and prevention. respiratory syncytial virus–united states, july 2012-june 2014. MMWR Morb Mortal Wkly Rep. 2014 Dec 05;63(48):1133–1136.
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Fishman JE, Cleary T, et al. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis. 2012;14(1):64–71.
   PubMed Web of Science ®Google Scholar
• Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 01;375(9725):1545–1555.
   PubMed Web of Science ®Google Scholar
• Lo MS, Lee GM, Gunawardane N, et al. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar;17(2):133–143.
   PubMed Web of Science ®Google Scholar
• Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958–962.
   PubMed Web of Science ®Google Scholar
• Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12):2114–2119.
   PubMed Web of Science ®Google Scholar
• Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12(1):38–44.
   PubMed Web of Science ®Google Scholar
• Pilie P, Werbel WA, Riddell J, et al. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis. 2015;17(4):551–557.
   PubMed Web of Science ®Google Scholar
• Anderson NW, Binnicker MJ, Harris DM, et al. Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review. Diagn Microbiol Infect Dis. 2016;85(3):367–371.
   PubMed Web of Science ®Google Scholar
• De Lima CR, Mirandolli TB, Carneiro LC, et al. Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis. 2014;16(1):165–169.
   PubMed Web of Science ®Google Scholar
• Li L, Avery R, Budev M, et al. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839–844.
   PubMed Web of Science ®Google Scholar
• Pelaez A, Gm L, Sd F, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28(1):67–71.
   PubMed Web of Science ®Google Scholar
• Uckay I, Gasche-Soccal PM, Kaiser L, et al. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant. 2010;29(3):299–305.
   PubMed Web of Science ®Google Scholar
• Wyde PR, Chetty SN, Jewell AM, et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60(1):51–59.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245–249.
   PubMed Web of Science ®Google Scholar
• Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872–1880.
   PubMed Web of Science ®Google Scholar
• Krinzman S, Basgoz N, Kradin R, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant. 1998;17(2):202–210.
   PubMed Web of Science ®Google Scholar
• Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14(3):479–485.
   PubMed Web of Science ®Google Scholar
• Shults RA, Baron S, Decker J, et al. Health care worker exposure to aerosolized ribavirin: biological and air monitoring. J Occup Environ Med. 1996;38(3):257–263.
   PubMed Web of Science ®Google Scholar
• Synagis prescribing information: AstraZeneca. Wilmington, DE; 2014.
   Google Scholar
• Grodin JL, Wu KS, Kitchell EE, et al. Respiratory syncytial virus pneumonia treated with lower-dose palivizumab in a heart transplant recipient. Case Rep Cardiol. 2012;2012:723407.
   PubMedGoogle Scholar
• Michaels MG, Fonseca-Aten M, Green M, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009;13(4):451–456.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126–144.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simoes EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125(1):e35–51.
   PubMed Web of Science ®Google Scholar
• MedImmune discontinues development of motavizumab for RSV prophylaxis indication. Available at: https://www.medimmune.com/about-us/media/medimmune-discontinues-development-of-motavizumab-for-rsv-prophylaxis-indication-20101221.html. Accessed December 12, 2016.
   Google Scholar
• Falsey AR, Koval C, DeVincenzo JP, et al. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis. 2017 January 5. published online. DOI:10.1111/tid.12657
   PubMed Web of Science ®Google Scholar
• Mackman RL, Sangi M, Sperandio D, et al. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630–1643.
   PubMed Web of Science ®Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2016;60(3):1264–1273.
   Web of Science ®Google Scholar
• DeVincenzo JP, McClure MW, Symons JA, et al. Activity of Oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the antiviral activity, clinical outcomes, safety, toelrability, and pharmacokinetics of orally administered ALS-008176 regimens in adult participants hospitalized with respiratory syncytial virus. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02935673?term=ALS-008176&rank=6. Accessed January 11, 2017.
   Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221.
   PubMed Web of Science ®Google Scholar
• Personal communication, Alnylam Pharmaceuticals, Cambridge, MA. 2017.
   Google Scholar
• Debur MC, Vidal LR, Stroparo E, et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12(2):173–179.
   PubMed Web of Science ®Google Scholar
• Dokos C, Masjosthusmann K, Rellensmann G, et al. Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2013;15(3):E97–E101.
   PubMed Web of Science ®Google Scholar
• Egli A, Bucher C, Dumoulin A, et al. Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation. Infection. 2012;40(6):677–684.
   PubMed Web of Science ®Google Scholar
• Kitanovski L, Kopriva S, Pokorn M, et al. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol. 2013;35(7):e311–3.
   PubMed Web of Science ®Google Scholar
• Schuster JE, Cox RG, Hastings AK, et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis. 2015;211(2):216–225.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl: 11S-5S.
   PubMed Web of Science ®Google Scholar
• Tran TT, Gonzalez IA, Tekin A, et al. Lower respiratory tract viral infections in pediatric abdominal organ transplant recipients: a single hospital inpatient cohort study. Pediatr Transplant. 2013;17(5):461–465.
   PubMed Web of Science ®Google Scholar
• Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33(12):2004–2008.
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Khare GP, Allen LB, et al. In vitro and in vivo effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) on types 1 and 3 parainfluenza virus infections. Chemotherapy. 1975;21(3–4):205–220.
   PubMed Web of Science ®Google Scholar
• Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010;202(2):234–241.
   PubMed Web of Science ®Google Scholar
• Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant. 2016;22(5):965–970.
   PubMedGoogle Scholar
• Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis. 2013;15(1):E28–32.
   PubMed Web of Science ®Google Scholar
• Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis. 2012;14(4):427–433.
   PubMed Web of Science ®Google Scholar
• A Phase II, randomized, double-blind, placebo-controlled study to examine the effects of DAS181 in immunocompromised subjects with lower respiratory tract parainfluenza infection on supplemental oxygen (DAS181-2-05). Available at: https://clinicaltrials.gov/ct2/show/NCT01644877?term=das181&rank=6. Accessed January 12, 2017.
   Google Scholar
• McLaughlin LP, Lang H, Williams E, et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016;18(12):1515–1524.
   PubMed Web of Science ®Google Scholar
• Shah DP, Ghantoji SS, Mulanovich VE, et al. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res. 2012;2(4):203–218.
   PubMedGoogle Scholar
• Bridevaux PO, Aubert JD, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69(1):32–38.
   PubMed Web of Science ®Google Scholar
• Lau SK, Yip CC, Woo PC, et al. Human rhinovirus C: a newly discovered human rhinovirus species. Emerg Health Threats J. 2010;3:e2.
   PubMedGoogle Scholar
• Costa C, Bergallo M, Astegiano S, et al. Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients. Arch Virol. 2011;156(8):1439–1443.
   PubMed Web of Science ®Google Scholar
• Pevear DC, Tull TM, Seipel ME, et al. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43(9):2109–2115.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36(12):1523–1532.
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Cloud G, Bradley J, et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003;22(4):335–341.
   PubMed Web of Science ®Google Scholar
• Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis. 2002;2(5):264.
   PubMed Web of Science ®Google Scholar
• Effects of pleconaril nasal spray on common cold symptoms and asthma exacerbations following rhinovirus exposure (Study P04295). Available at: https://clinicaltrials.gov/ct2/show/NCT00394914?term=pleconaril&rank=1. Accessed January 12, 2017.
   Google Scholar
• Pleconaril enteroviral sepsis syndrome. Available at: https://clinicaltrials.gov/ct2/show/NCT00031512?term=pleconaril&rank=2. Accessed January 12, 2017.
   Google Scholar
• Brown RN, Cameron R, Chalmers DK, et al. 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. Bioorg Med Chem Lett. 2005;15(8):2051–2055.
   PubMed Web of Science ®Google Scholar
• A Phase 2 study of BTA798 in asthmatic adults with symptomatic human rhinovirus infection (RHINO). Available at: https://clinicaltrials.gov/ct2/show/NCT01175226?term=bta+798&rank=1. Accessed January 12, 2017.
   Google Scholar
• Huang X, Zhang X, Wang F, et al. Clinical efficacy of therapy with recombinant human interferon alpha1b in hand, foot, and mouth disease with enterovirus 71 infection. Plos One. 2016;11(2):e0148907.
   PubMed Web of Science ®Google Scholar
• Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial (Hypogamma Int1). Available at: https://clinicaltrials.gov/ct2/show/NCT02661477?term=interferon+alpha+rhinovirus&rank=1. Accessed January 12, 2017.
   Google Scholar
• Djukanovic R, Harrison T, Johnston SL, et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014;190(2):145–154.
   PubMed Web of Science ®Google Scholar
• Bice JB, Leechawengwongs E, Montanaro A. Biologic targeted therapy in allergic asthma. Ann Allergy Asthma Immunol. 2014;112(2):108–115.
   PubMed Web of Science ®Google Scholar
• Effect of OC459 on the response to rhinovirus challenge in asthma. Available at: https://clinicaltrials.gov/ct2/show/NCT02660489?term=oc459+rhinovirus&rank=1. Accessed January 12, 2017.
   Google Scholar
• Treatment with omalizumab to improve the asthmatic response to rhinovirus experimental infection with rhinovirus. Available at: https://clinicaltrials.gov/ct2/show/NCT02388997?term=omalizumab+rhinovirus&rank=1. Accessed January 12, 2017.
   Google Scholar
• Thibaut HJ, De Palma AM, Neyts J. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012;83(2):185–192.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis. 2002;185(9):1338–1341.
   PubMed Web of Science ®Google Scholar
• Heugel J, Martin ET, Kuypers J, et al. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J. 2007;26(8):753–755.
   PubMed Web of Science ®Google Scholar
• Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893.
   PubMed Web of Science ®Google Scholar
• Aleanizy FS, Mohmed N, Alqahtani FY. El Hadi Mohamed RA. outbreak of middle east respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. BMC Infect Dis. 2017;17(1):23.
   PubMed Web of Science ®Google Scholar
• AlGhamdi M, Mushtaq F, Awn N, et al. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant. 2015;15(4):1101–1104.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46.
   PubMed Web of Science ®Google Scholar
• MERS-CoV infection treated with a combination of lopinavir /ritonavir and interferon beta-1b (MIRACLE). Available at: https://clinicaltrials.gov/ct2/show/NCT02845843?term=coronavirus&rank=5. Accessed January 12, 2017.
   Google Scholar
• Anti-MERS-COV convalescent plasma therapy. Available at: https://clinicaltrials.gov/ct2/show/study/NCT02190799?term=coronavirus&rank=8. Accessed January 9, 2017.
   Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial. Biol Blood Marrow Transplant. 2016;22(3):S23.
   PubMed Web of Science ®Google Scholar
• Gerna G, Piralla A, Rovida F, et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol. 2009;81(8):1498–1507.
   PubMed Web of Science ®Google Scholar
• Ac VDP, Tf W, Am VL, et al. Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection. J Clin Microbiol. 2010;48(10):3569–3574.
   PubMed Web of Science ®Google Scholar
• Saglio F, Hanley PJ, Bollard CM. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy. 2014;16(2):149–159.
   PubMed Web of Science ®Google Scholar
• Bekerman E, Einav S. Infectious disease. Combating emerging viral threats. Science. 2015;348(6232):282–283.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Sato Y, Sasaki T. Suppression of coronavirus replication by cyclophilin inhibitors. Viruses. 2013;5(5):1250–1260.
   PubMed Web of Science ®Google Scholar